Ace the Case: A 53-Year-Old Woman with Shortness of Breath on Exertion

Summary and References

Summary

Pulmonary arterial hypertension, although uncommon, leads to significant mortality, morbidity, and healthcare costs for affected patients. Given its rarity and complex pathophysiology, PAH is often misdiagnosed and suboptimally treated. Physicians should maintain a high index of suspicion when patients present with dyspnea on exertion and know the criteria to look for on echocardiogram. All patients with suspected PAH should be referred immediately for a right-heart catheterization so that treatment can be started. New research has shown that combination therapy, targeting one or more pathological processes in PAH, is preferred to monotherapy. Early treatment is critical as well. By starting early combination treatment, clinicians can improve survival and quality of life for patients with PAH.

References

  1. Galiè N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119.
  2. Hoeper MM, et al. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014;23(134):450-7.
  3. Brown LM, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140(1):19-26.
  4. Thenappan T, et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2017;30(6):1103-10.
  5. McLaughlin VV, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-63.
  6. Mukerjee D, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088-93.
  7. Burger CD, et al. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731-9.
  8. Taichman DB, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449-75.
  9. Badesch DB, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87.
  10. Hoeper MM, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-50.
  11. McLaughlin VV, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-619.
  12. Stringham R, Shah NR. Pulmonary arterial hypertension: an update on diagnosis and treatment. American Family Physician. 2010;82(4):370-7.
  13. Barst RJ, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632-43.
  14. McLaughlin VV, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13.
  15. Sitbon O, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-33.
  16. Pulido T, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-18.
  17. Simonneau G, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-30.
  18. Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40.
  19. Ruopp NF, Farber HW. Gaps and controversies of new treatment recommendations in recent pulmonary hypertension guidelines: what we know and what we don't. Advances in Pulmonary Hypertension. 2016;16(1):20-5.
  20. Galiè N, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-44.
  21. Coghlan JG, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219-27.
  22. Hassoun PM, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(9):1102-10.
  23. Humbert M, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9.
  24. To compare the efficacy of combination therapy vs monotherapy for pulmonary arterial hypertension in systemic sclerosis. NIH U.S. National Library of Medicine Clincaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT03053739. Accessed October 29, 2018.
  25. Clinical study evaluating the effects of first-line oral combination therapy of macitentan and tadalafIl in patients with newly diagnosed pulmonary arterial hypertension (OPTIMA). NIH U.S. National Library of Medicine Clincaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02968901. Accessed October 29, 2018.
  26. Sitbon O, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7.
  27. The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). U.S. National Library of Medicine Clincaltrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02558231. Accessed October 29, 2018.
  28. Farber HW, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043-54.
Back